SAVA – cassava sciences, inc. (US:NASDAQ)

News

IGC Pharma posts promising interim data for Alzheimer's therapy [Yahoo! Finance]
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study [Yahoo! Finance]
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug [Yahoo! Finance]
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com